The Virax Team Visits its New Laboratory in Scale Space White City at Imperial College London

The Virax Team Visits its New Laboratory in Scale Space White City at Imperial College London

This past week, the Virax Biolabs team was pleased to meet in West London to tour our recently announced laboratory space in Scale Space White City at Imperial College London. In tandem with the establishment of our new Research and Development facilities at BioCity Glasgow, Scale Space is an augmentation for the future roll out of our flagship ViraxImmune™ platform.

A Hub of Innovation

The 200,000 square foot incubator proved to be a truly impressive environment that would be conducive to transformative growth. As we explored the physical space, the vibrant atmosphere of innovation and collaboration was definitely palpable.

WhatsApp Image 2023 07 12 at 08.13.44

James Foster (CEO) & Cameron Shaw (COO) at Scale Space’s dedicated recording facilities

Due to Scale Space’s strategic location in major metropolitan London, the facility is especially well-suited to offer tailored and collaborative environment for high-growth businesses and scaleups such as Virax. Complete with phlebotomy stations, laboratories, research facilities, and various meeting spaces, the seamless integration of cutting-edge resources provides an ecosystem conducive for fostering creativity and progress towards novel life science advancements.

A Step Towards ViraxImmune™

WhatsApp Image 2023 07 12 at 08.13.441

The team visits our dedicated laboratory space: from left to right - Alan Yang (Growth Manager), Richard Pallin (VP of IVD Sales), Clément Monteil (Head of Scientific R&D), Cameron Shaw (COO), James Foster (CEO)

Our visit revealed the amazing potential of our partnership with Scale Space White City. Pending regulatory approval, this state-of-the-art laboratory facility would serve as a launchpad for our innovative ViraxImmune™ offering, our very first laboratory for blood draw and immune response analysis. Under these arrangements, the facility’s capabilities could enable us to fulfill third-party laboratory orders, to enhance our comprehensive range of available diagnostics and capacity for partner services.

Our visit to Scale Space White City was an exciting opportunity for us to visualize the potential of this partnership in a new light: the cutting-edge facilities and resources at Scale Space hold promise for accelerating our growth and fulfilling our mission. As we progress, we are committed to transforming healthcare and empowering individuals with personalized in-vitro diagnostic solutions through ViraxImmune™. With Scale Space as a collaborative partner, we look forward to the possibilities that lie ahead, working diligently towards a healthier future.

Caution Concerning Forward Looking Statements: This blog post contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives might not occur.

Media and Investor Contact:

  • Nic Johnson and Adanna Alexander
  • Russo Partners, LLC
  • +1 (303) 482-6405